News
VENTANA FOLR1 (FOLR1-2.1) RxDx Assay – Roche’s immunohistochemistry (IHC) companion diagnostic for identifying ovarian patients eligible for ELAHERE – has been contemporaneously approved by ...
Hosted on MSN5mon
Roche secures CE mark for ovarian cancer detection testVENTANA FOLR1 (FOLR1-2.1) RxDx Assay, for the identification of epithelial ovarian cancer (EOC) patients suitable for targeted therapy with AbbVie’s ELAHERE (mirvetuximab soravtansine).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback